• Earlier this month, Globus Medical reported strong third-quarter results with significant increases in sales and net income, raised its full-year 2025 revenue forecast, and confirmed recent share repurchases under its buyback program.
• An important insight is that Globus Medical's management emphasized a capital allocation strategy prioritizing innovation, internal investment, and selective acquisitions alongside share buybacks to support long-term value creation for shareholders.
• We'll explore how the robust quarterly performance and raised outlook may further reinforce Globus Medical's investment narrative around innovation and market expansion.

We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Globus Medical Investment Narrative Recap

To be a Globus Medical shareholder, you have to believe in the company's ability to drive sustained innovation in spine and orthopedics, execute on major acquisitions, and expand internationally, while successfully managing operational risks. The latest quarterly results and raised outlook support the innovation and margin expansion narrative, but do not materially change the fact that integration execution and unpredictable sales cycles in enabling technologies remain the most important near-term catalyst and risk, respectively.

The company's announcement of its recent share buyback is directly relevant because it confirms management's ongoing focus on long-term value creation even as integration efforts and international expansion continue. While buybacks can support earnings per share in the short term, the effectiveness will still depend on Globus's ability to absorb acquisitions and maintain revenue momentum in key global markets.

However, investors should also be aware of persistent challenges in international markets and how distributor transitions might impact future sales performance...

Globus Medical's narrative projects $3.4 billion revenue and $538.8 million earnings by 2028. This requires 9.0% yearly revenue growth and a $182.2 million increase in earnings from $356.6 million.

Uncover how Globus Medical's forecasts yield a $88.80 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Five private investors in the Simply Wall St Community see fair value for Globus Medical anywhere from US$17.32 to US$90. Integration execution risk remains top of mind as you weigh these very different outlooks against current business performance.

Explore 5 other fair value estimates on Globus Medical - why the stock might be worth less than half the current price!

Build Your Own Globus Medical Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Globus Medical research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Globus Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globus Medical's overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.